| 1 | The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families | 2.3 | 7 | Citations (PDF) |
| 2 | Expression and Localization of Ferritin-Heavy Chain Predicts Recurrence for Breast Cancer Patients with a BRCA1/2 Mutation | 3.8 | 3 | Citations (PDF) |
| 3 | Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient | 3.8 | 8 | Citations (PDF) |
| 4 | Genetic drivers and cellular selection of female mosaic X chromosome loss | 37.9 | 32 | Citations (PDF) |
| 5 | Cancer risks for other sites in addition to breast in CHEK2 c.1100delC families | 4.2 | 10 | Citations (PDF) |
| 6 | Cohort profile: a nationwide study in Dutch
CHEK2
c.1100delC families using the infrastructure of the HEreditary Breast and Ovarian cancer study Netherlands – Hebon-CHEK2 | 1.9 | 1 | Citations (PDF) |
| 7 | Polygenic score distribution differences across European ancestry populations: implications for breast cancer risk prediction | 4.8 | 11 | Citations (PDF) |
| 8 | Clinical applicability of the Polygenic Risk Score for breast cancer risk prediction in familial cases | 3.8 | 34 | Citations (PDF) |
| 9 | FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women | 3.0 | 10 | Citations (PDF) |
| 10 | Genome-wide analyses characterize shared heritability among cancers and identify novel cancer susceptibility regions | 4.6 | 29 | Citations (PDF) |
| 11 | Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile | 4.8 | 7 | Citations (PDF) |
| 12 | Spectrum and Frequency of Germline FANCM Protein-Truncating Variants in 44,803 European Female Breast Cancer Cases | 3.8 | 1 | Citations (PDF) |
| 13 | Association of the
CHEK2
c.
1100delC
variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer‐specific survival | 2.6 | 5 | Citations (PDF) |
| 14 | Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel | 3.8 | 3 | Citations (PDF) |
| 15 | Rare germline copy number variants (CNVs) and breast cancer risk | 4.4 | 12 | Citations (PDF) |
| 16 | Common variants in breast cancer risk loci predispose to distinct tumor subtypes | 4.8 | 26 | Citations (PDF) |
| 17 | Identifying Transcripts with Tandem Duplications from RNA-Sequencing Data to Predict BRCA1-Type Primary Breast Cancer | 3.8 | 1 | Citations (PDF) |
| 18 | A pipeline for copy number profiling of single circulating tumour cells to assess intrapatient tumour heterogeneity | 4.1 | 8 | Citations (PDF) |
| 19 | Breast cancer risks associated with missense variants in breast cancer susceptibility genes | 9.6 | 51 | Citations (PDF) |
| 20 | Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry | 3.8 | 3 | Citations (PDF) |
| 21 | Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study | 10.6 | 61 | Citations (PDF) |
| 22 | Progression-free survival and overall survival after BRCA1/2-associated epithelial ovarian cancer: A matched cohort study | 2.3 | 5 | Citations (PDF) |
| 23 | Common Susceptibility Loci for Male Breast Cancer | 4.6 | 20 | Citations (PDF) |
| 24 | A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers | 13.7 | 37 | Citations (PDF) |
| 25 | Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women | 34.6 | 956 | Citations (PDF) |
| 26 | The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant | 4.2 | 29 | Citations (PDF) |
| 27 | Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element | 6.5 | 7 | Citations (PDF) |
| 28 | Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis | 3.4 | 3 | Citations (PDF) |
| 29 | Genetically Predicted Levels of DNA Methylation Biomarkers and Breast Cancer Risk: Data From 228 951 Women of European Descent | 4.6 | 48 | Citations (PDF) |
| 30 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes | 25.2 | 166 | Citations (PDF) |
| 31 | Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk | 6.5 | 56 | Citations (PDF) |
| 32 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses | 25.2 | 437 | Citations (PDF) |
| 33 | Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk | 3.4 | 4 | Citations (PDF) |
| 34 | Transcriptome‐wide association study of breast cancer risk by estrogen‐receptor status | 3.1 | 42 | Citations (PDF) |
| 35 | The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer | 6.4 | 42 | Citations (PDF) |
| 36 | Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-<i>BRCA1/2</i>breast cancer families | 3.8 | 45 | Citations (PDF) |
| 37 | Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer | 13.7 | 116 | Citations (PDF) |
| 38 | Genome-wide association study of germline variants and breast cancer-specific mortality | 5.5 | 62 | Citations (PDF) |
| 39 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes | 6.5 | 989 | Citations (PDF) |
| 40 | Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis | 4.9 | 91 | Citations (PDF) |
| 41 | The BRCA2
c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity | 4.5 | 20 | Citations (PDF) |
| 42 | Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation | 4.3 | 27 | Citations (PDF) |
| 43 | Elucidating the Underlying Functional Mechanisms of Breast Cancer Susceptibility Through Post-GWAS Analyses | 2.3 | 15 | Citations (PDF) |
| 44 | A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk | 3.8 | 64 | Citations (PDF) |
| 45 | The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome | 3.8 | 24 | Citations (PDF) |
| 46 | A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer | 25.2 | 226 | Citations (PDF) |
| 47 | BRCA2
Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer | 3.8 | 87 | Citations (PDF) |
| 48 | Low Tumor Mitochondrial DNA Content Is Associated with Better Outcome in Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy | 6.8 | 17 | Citations (PDF) |
| 49 | Association analysis identifies 65 new breast cancer risk loci | 37.9 | 1,398 | Citations (PDF) |
| 50 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer | 25.2 | 394 | Citations (PDF) |
| 51 | Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study | 4.8 | 45 | Citations (PDF) |
| 52 | Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus | 2.3 | 12 | Citations (PDF) |
| 53 | The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer | 2.3 | 17 | Citations (PDF) |
| 54 | Fine‐scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer | 4.3 | 53 | Citations (PDF) |
| 55 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS | 3.8 | 204 | Citations (PDF) |
| 56 | Recurrent HOXB13 mutations in the Dutch population do not associate with increased breast cancer risk | 3.4 | 3 | Citations (PDF) |
| 57 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus | 4.8 | 37 | Citations (PDF) |
| 58 | Genetic predisposition to ductal carcinoma in situ of the breast | 4.8 | 54 | Citations (PDF) |
| 59 | rs2735383, located at a microRNA binding site in the 3’UTR of NBS1, is not associated with breast cancer risk | 3.4 | 2 | Citations (PDF) |
| 60 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer | 13.7 | 103 | Citations (PDF) |
| 61 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus | 13.7 | 88 | Citations (PDF) |
| 62 | Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs) | 3.4 | 21 | Citations (PDF) |
| 63 | Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups | 4.8 | 66 | Citations (PDF) |
| 64 | GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease | 8.6 | 26 | Citations (PDF) |
| 65 | High‐throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium | 3.3 | 19 | Citations (PDF) |
| 66 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170 | 25.2 | 148 | Citations (PDF) |
| 67 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer | 3.0 | 20 | Citations (PDF) |
| 68 | A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients | 2.9 | 10 | Citations (PDF) |
| 69 | Common germline polymorphisms associated with breast cancer-specific survival | 4.8 | 29 | Citations (PDF) |
| 70 | Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants | 4.6 | 482 | Citations (PDF) |
| 71 | Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium | 3.3 | 25 | Citations (PDF) |
| 72 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2 | 2.9 | 40 | Citations (PDF) |
| 73 | Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1 | 6.5 | 81 | Citations (PDF) |
| 74 | Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast cancer | 2.3 | 27 | Citations (PDF) |
| 75 | Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer | 2.8 | 18 | Citations (PDF) |
| 76 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer | 25.2 | 573 | Citations (PDF) |
| 77 | Identification of Novel Genetic Markers of Breast Cancer Survival | 4.6 | 65 | Citations (PDF) |
| 78 | Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis | 7.1 | 57 | Citations (PDF) |
| 79 | Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers | 2.3 | 11 | Citations (PDF) |
| 80 | Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk | 1.1 | 25 | Citations (PDF) |
| 81 | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk | 2.9 | 39 | Citations (PDF) |
| 82 | Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast | 3.2 | 44 | Citations (PDF) |
| 83 | 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy | 13.7 | 16 | Citations (PDF) |
| 84 | Growth and metastatic behavior of molecularly well-characterized human breast cancer cell lines in mice | 2.4 | 6 | Citations (PDF) |
| 85 | Analysis of TP53 Mutation Status in Human Cancer Cell Lines: A Reassessment | 4.5 | 199 | Citations (PDF) |
| 86 | A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium | 2.9 | 34 | Citations (PDF) |
| 87 | Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy | 5.5 | 68 | Citations (PDF) |
| 88 | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study | 4.8 | 14 | Citations (PDF) |
| 89 | miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs | 4.8 | 195 | Citations (PDF) |
| 90 | Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer | 2.4 | 123 | Citations (PDF) |
| 91 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer | 25.2 | 514 | Citations (PDF) |
| 92 | Genome-wide association studies identify four ER negative–specific breast cancer risk loci | 25.2 | 396 | Citations (PDF) |
| 93 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk | 25.2 | 1,020 | Citations (PDF) |
| 94 | CHEK2*1100delC homozygosity in the Netherlands—prevalence and risk of breast and lung cancer | 3.0 | 37 | Citations (PDF) |
| 95 | E-cadherin promotor methylation and mutation are inversely related to motility capacity of breast cancer cells | 2.4 | 27 | Citations (PDF) |
| 96 | Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk | 25.2 | 104 | Citations (PDF) |
| 97 | Genome-wide association analysis identifies three new breast cancer susceptibility loci | 25.2 | 271 | Citations (PDF) |
| 98 | 9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium | 1.1 | 17 | Citations (PDF) |
| 99 | Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor–Positive, Lower Grade Breast Cancer | 1.1 | 27 | Citations (PDF) |
| 100 | Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies | 4.6 | 626 | Citations (PDF) |
| 101 | Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium | 2.9 | 156 | Citations (PDF) |
| 102 | A 3′-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis | 27.4 | 138 | Citations (PDF) |
| 103 | A genome-wide association scan on estrogen receptor-negative breast cancer | 4.8 | 35 | Citations (PDF) |
| 104 | Discovering moderate-risk breast cancer susceptibility genes | 3.2 | 107 | Citations (PDF) |
| 105 | Prevalence of the variant allele rs61764370 T>G in the 3′UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families | 2.4 | 35 | Citations (PDF) |
| 106 | Comment Re: MDA-MB-435 and M14 Cell Lines: Identical but not M14 Melanoma? | 3.8 | 36 | Citations (PDF) |
| 107 | Low-risk susceptibility alleles in 40 human breast cancer cell lines | 2.9 | 27 | Citations (PDF) |
| 108 | Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines | 2.4 | 264 | Citations (PDF) |
| 109 | Four human breast cancer cell lines with biallelic inactivating α-catenin gene mutations | 2.4 | 40 | Citations (PDF) |
| 110 | Exon Expression Arrays as a Tool to Identify New Cancer Genes | 2.3 | 13 | Citations (PDF) |
| 111 | Deleterious CHEK2 1100delC and L303X mutants identified among 38 human breast cancer cell lines | 2.4 | 9 | Citations (PDF) |
| 112 | Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines | 3.1 | 293 | Citations (PDF) |
| 113 | Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations | 25.2 | 1,052 | Citations (PDF) |
| 114 | Outcomes for ER-positive CHEK2 c.1100delC breast cancer patients compared with breast cancer patients without the variant | 2.3 | 0 | Citations (PDF) |
| 115 | Large-scale meta-analysis and precision functional assays identify FANCM regions in which PTVs confer different risks for ER-negative and triple-negative breast cancer | 2.3 | 0 | Citations (PDF) |
